# Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients

> **NCT07485764** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 186 (estimated)

## Conditions studied

- Psoriasis
- Plaque Psoriasis
- Moderate-to-severe Plaque Psoriasis
- Overweight , Obesity

## Interventions

- **DRUG:** Secukinumab 300mg s.c.
- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07485764
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2026-06
- **Final completion:** 2029-06
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07485764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07485764, "Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07485764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*